Faculty & Staff

Mario Strazzabosco, MD, PhD, was appointed Director and Clinical Program Leader of the Smilow Liver Cancer Program on January 1, 2017. With expertise in advanced hepatology, Dr. Strazzabosco is an expert in the care of patients with liver cancer. Dr. Strazzabosco returned to Yale after serving as the Founding Chief of the Section of Digestive Diseases, Chair of the Department of Surgery and Translational Medicine, and Vice President of the School of Medicine at the University of Milan. He is internationally known for his work in Hepatology and Liver Transplantation, previously served as Medical Director of Hepatology at Yale, is a recipient of NIH funding, and is a member of several scientific societies in Europe and in the United States. Dr. Strazzabosco holds an appointment as Professor of Medicine (Digestive Diseases) at Yale School of Medicine and as Co-Director of the Yale Liver Center. As leader of the Liver Cancer Program at Smilow Cancer Hospital, Dr. Strazzabosco coordinates the efforts of the team to further develop the program in collaboration with the specialties of Medical Oncology, Interventional Radiology, Surgical Oncology, Hepatology, and Transplantation Surgery.

Enthusiastic and adaptable Scientist with hands-on experience in data analysis, artificial intelligence, and Big Data. I follow a Data Driven Decision Making approach, enabling me to tackle challenges with pragmatism and strategic insight. Passionate about driving Digital Transformation, I aim to contribute to innovative projects that leverage technology to create meaningful impact.

After a Medical degree at Padua University, Italy (1987), Luca Fabris achieved his PhD at University of Milan, Italy (1997), by means of a research program developed at University of Birmingham, UK (1995-96). In 2005, he was nominated assistant Professor at the University of Padua, School of Medicine, promoted to associate Professor in Gastroenterology in 2016. Since 2023, Dr Fabris has been serving as Vice-President of the School of Medicine and Surgery, University of Padua (English course). Over the last 25 years, he has focused his scientific interests on topics related to pathophysiology of chronic liver diseases, biliary in particular, both of inflammatory and neoplastic origin, mainly with translational studies. From 2012, he has joined the Yale Liver Center faculty with an adjunct appointment (currently Associate Professor), where he is involved in the program of genetic biliary diseases, cancers and gender-specific differences in liver diseases. From 2024, he is Fellow of the American Association for the Study of Liver Disease (FAASLD). Currently, Dr Fabris is serving as Associate Editor for Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, and as Editorial Board member of Hepatology, American Journal of Physiology – Gastrointestinal and Liver Physiology, and International Journal of Sex and Gender Medicine. He has been serving as external expert and/or expert panelist of several European grant agencies (HCERES, NCN, COST, ERC among others).